6 results on '"Brighenti, Matteo"'
Search Results
2. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- Author
-
Petrelli, Fausto, Grizzi, Giulia, Ghidini, Michele, Ghidini, Antonio, Ratti, Margherita, Panni, Stefano, Cabiddu, Mary, Ghilardi, Mara, Borgonovo, Karen, Parati, Maria C., Tomasello, Gianluca, Barni, Sandro, Berruti, Alfredo, and Brighenti, Matteo
- Abstract
Supplemental Digital Content is available in the text.Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We performed a systematic review and meta-analysis of the published literature to assess the outcome for cancer patients treated with ICIs who develop irAEs. Two independent reviewers selected prospective or retrospective studies from PubMed, EMBASE, and the Cochrane Library database from their inception to November 2018. Data were pooled using hazard ratios (HRs) for overall survival or progression-free survival or odds ratio for overall response rate of irAEs versus no irAEs according to fixed or random-effect model. HRs for OS (the primary outcome measure) were pooled to provide an aggregate value. A total of 30 studies that included a total of 4324 patients treated with ICIs were selected. Patients who developed irAEs presented a reduced risk of death [HR=0.49, 95% confidence interval (CI): 0.38–0.62; P<0.001]. Similarly, the occurrence of irAEs was associated with a reduced risk of progression (HR=0.51, 95% CI: 0.42–0.64; P<0.001). The odds of response was 4.56 (95% CI: 3.72–5.59; P<0.001). In patients treated with ICIs, irAEs predict survival and response. Although this correlation cannot be fully explained, it may be related to the strongest T-cell activation.
- Published
- 2020
- Full Text
- View/download PDF
3. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
- Author
-
Tiseo, Marcello, Boni, Luca, Ambrosio, Francesca, Camerini, Andrea, Baldini, Editta, Cinieri, Saverio, Brighenti, Matteo, Zanelli, Francesca, Defraia, Efisio, Chiari, Rita, Dazzi, Claudio, Tibaldi, Carmelo, Turolla, Gianni Michele, D'Alessandro, Vito, Zilembo, Nicoletta, Trolese, Anna Rita, Grossi, Francesco, Riccardi, Ferdinando, and Ardizzoni, Andrea
- Published
- 2017
- Full Text
- View/download PDF
4. Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer
- Author
-
Liguigli, Wanda, Tomasello, Gianluca, Toppo, Laura, Poli, Rossana, Lazzarelli, Silvia, Negri, Federica, Perrucci, Bruno, Curti, Alessandra, Brighenti, Matteo, Donati, Gianvito, Nazzari, Morena, Martinotti, Mario, Vismarra, Marco, Rovatti, Massimo, and Passalacqua, Rodolfo
- Abstract
Purpose To evaluate the efficacy and safety of dose-dense TCF in elderly (≥65 years) compared to younger patients.Methods Safety and efficacy data relative to 119 consecutive patients with locally advanced or metastatic gastric cancer treated at our institution and enrolled in different phase II trials were retrospectively collected. All patients were treatment-naive and received docetaxel 70 mg/m2day 1, cisplatin 60 mg/m2day 1, l-folinic acid 100 mg/m2days 1-2, followed by 5-fluorouracil 400 mg/m2bolus days 1-2, and then 600 mg/m2as a 22-hour continuous infusion days 1-2, every 14 days, plus pegfilgrastim 6 mg on day 3. Sixty patients (50%) aged ≥65 years received the same schedule with a dose reduction by 30%.Results A total of 86% of patients were evaluable for response and all for toxicity. In patients aged ≥65 years, we observed an overall response rate of 51%. Median overall survival was 11.2 (95% confidence interval [CI] 7.3-15.1) and 11.8 months (95% CI 9.2-16.2) in elderly and younger patients, respectively. In the elderly patients, the most frequent grade 3-4 toxicities were neutropenia (13%), leukopenia (7%), thrombocytopenia (18%), anemia (3%), and febrile neutropenia (8%); in the younger patients, neutropenia (56%), leucopenia (31%), thrombocytopenia (22%), anemia (15%), and febrile neutropenia (15%).Conclusions Elderly patients can be safely treated with a dose-dense TCF regimen with a 30% dose reduction achieving similar efficacy results as younger patients with lesser toxicity.
- Published
- 2017
- Full Text
- View/download PDF
5. Dose-dense Chemotherapy in Metastatic Gastric Cancer with a Modified Docetaxel-Cisplatin-5-Fluorouracil Regimen
- Author
-
Tomasello, Gianluca, Chiesa, Matteo Dalla, Buti, Sebastiano, Brighenti, Matteo, Negri, Federica, Rovere, Rodrigo Kraft, Martinotti, Mario, Buononato, Massimo, Brunelli, Antonio, Lazzarelli, Silvia, Donati, Gianvito, and Passalacqua, Rodolfo
- Abstract
Aims and background Previous studies have reported that in early breast cancer, lymphomas and advanced bladder cancer, dose-dense chemotherapy may be more effective than conventional treatments. In metastatic gastric cancer, chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TCF) q3w is very active, and, even though there is no international consensus on the subject, it is the regimen of choice of many European centers as first-line chemotherapy in this subset of patients. Based on these studies, we tested for the first time the feasibility and activity of an intensified dose-dense TCF regimen (q2w) modifying the 5-fluorouracil infusion with l-folinic acid/5-fluorouracil according to the “De Gramont regimen”.Methods and study design Patients with histologically confirmed measurable metastatic gastric cancer, ECOG performance status ≤1, and not previously treated for advanced disease received docetaxel, 85 mg/m2(75 mg/m2after the first 6 patients, 70 mg/m2after the 19thpatient) on day 1, cisplatin, 75 mg/m2on day 1 (60 mg/m2after the 19th patient), l-folinic acid, 100 mg/m2on days 1 and 2, followed by 5-fluorouracil, 400 mg/m2bolus on days 1 and 2 and then 600 mg/m2as a 22-h continuous infusion on days 1 and 2, every 14 days, plus pegfilgrastim, 6 mg on day 3. Patients aged ≥65 years received the same schedule with a dose reduction of 30%.Results Thirty-two consecutive patients were enrolled (63% male, 37% female); median age, 64 years (range, 40–81). A median of 4 cycles (range, 1–7) per patient was administered. Eleven of 32 patients (34%) required a dose reduction, mostly for hematological grade III-IV toxicity and severe asthenia. Twelve patients (38%) completed the first 4 cycles of therapy within 7 weeks, thereby finishing without delay the initially planned dose-density schedule. Twenty-eight patients were evaluated for response (1 early suspension after the first cycle because of toxicity, 3 deaths before response evaluation due to progression of disease). There were 3 complete responses (9%), 15 partial responses (47%), 7 stable disease (22%) and 3 progression of disease (9%), for an overall response rate, by intention to treat, of 56% (95% CI, 39–73). The most frequent grade 3–4 toxicities were: neutropenia (53%), thrombocytopenia (34%), anemia (16%) febrile neutropenia (22%), asthenia (38%) and diarrhea (19%). Median time to progression was 9.1 months (95% CI, 6.0–12.2); median overall survival was 10.1 months (95% CI, 8.8–12.2).Conclusions A dose-dense TCF regimen in metastatic gastric cancer is feasible, with activity comparable to previous results achieved with epirubicin-based chemotherapy and TCF q3wk in terms of overall survival and time to progression, and deserves to be further tested in randomized phase III studies.
- Published
- 2010
- Full Text
- View/download PDF
6. A Pilot Phase ii Study of Chemotherapy with Oxaliplatin, Folinic acid, 5-Fluorouracil and Irinotecan in Metastatic Gastric Cancer
- Author
-
Chiesa, Matteo Dalla, Buti, Sebastiano, Tomasello, Gianluca, Negri, Federica, Buononato, Massimo, Brunelli, Antonio, Lazzarelli, Silvia, Brighenti, Matteo, Donati, Gianvito, and Passalacqua, Rodolfo
- Abstract
Aims and background Previous phase II studies have reported that combinations of oxaliplatin, folinic acid and 5-fluorouracil or irinotecan, folinic acid and 5-fluorouracil are associated with good efficacy and an acceptable safety profile in metastatic gastric cancer. The aim of this study was to evaluate chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI regimen) in metastatic gastric cancer.Methods Patients received oxaliplatin (85 mg/m2d 1), irinotecan (140 mg/m2d 1), and L-folinic acid (200 mg/m2d 1) followed by 5-fluorouracil bolus (400 mg/m2d 1) and then 5-fluorouracil (2,400 mg/m248-h continuous infusion), every 14 days.Results Seventeen patients with metastatic gastric cancer were enrolled. Eight patients were pretreated for advanced disease. Of the 9 chemo-naïve patients, 8 were evaluated for response (1 patient was lost to follow-up): one complete response, 5 partial responses and 2 progressions of disease occurred, giving an overall response rate, at intention-to-treat analysis, of 67%. Of the 8 pretreated patients, 6 were evaluated for response (2 patients had nonmeasurable disease): one partial response, 2 disease stabilizations and 3 progressions of disease occurred, giving an overall response rate, at intention-to-treat analysis, of 12%. Median progression-free and overall survival in chemo-naïve patients were 8.2 and 10.2 months, respectively, and in pretreated patients 2.7 and 3 months. Grade 3-4 neutropenia occurred in 55% of chemo-naïve patients. Thrombocytopenia, and anemia were observed in 18% and 29%, respectively. Grade 3 nausea/vomiting occurred in 12% and grade 3 diarrhea in 6%.Conclusions The COFFI regimen is active and well tolerated, therefore phase III studies are warranted.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.